William Blair Has Bearish Estimate for RARE Q4 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at William Blair cut their Q4 2026 EPS estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Monday, July 14th. William Blair analyst S. Corwin now anticipates that the biopharmaceutical company will earn $0.99 per share for the quarter, down from their prior estimate of $1.09. William Blair currently has a “Outperform” rating and a $65.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The firm had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same period in the prior year, the company posted ($2.03) earnings per share. The company’s revenue for the quarter was up 28.0% compared to the same quarter last year.

A number of other equities research analysts have also commented on RARE. JPMorgan Chase & Co. upped their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Guggenheim reaffirmed a “buy” rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Wedbush reduced their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research note on Monday. Morgan Stanley cut their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Wells Fargo & Company cut their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, July 10th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $83.64.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $27.20 on Tuesday. The firm’s fifty day moving average is $36.12 and its 200-day moving average is $38.53. Ultragenyx Pharmaceutical has a 52 week low of $26.85 and a 52 week high of $60.37. The firm has a market cap of $2.57 billion, a P/E ratio of -4.63 and a beta of 0.26.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company’s stock, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 3,167 shares of company stock valued at $118,824 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company’s stock valued at $422,167,000 after buying an additional 89,389 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Ultragenyx Pharmaceutical by 28.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company’s stock valued at $116,559,000 after buying an additional 706,519 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Ultragenyx Pharmaceutical by 81.6% in the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock valued at $77,815,000 after buying an additional 965,919 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company’s stock valued at $74,419,000 after buying an additional 5,400 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Ultragenyx Pharmaceutical by 0.5% in the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company’s stock valued at $61,611,000 after buying an additional 8,385 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.